Severe migraines result from a cascade of neurological events, not just a bad headache. The process involves overactive nerve signaling, blood vessel changes in the brain, and shifts in brain chemistry that amplify pain far beyond what most people experience with tension headaches. Understanding what drives this cascade can help you identify your personal triggers and recognize when occasional migraines are becoming something more chronic.
The Pain Pathway Behind a Migraine
Every migraine begins with activation of the trigeminovascular system, a network connecting the trigeminal nerve (the largest nerve in your face and head) to the blood vessels lining your brain. When this system fires, sensory nerve fibers running along the brain’s outer covering send pain signals through a relay station called the trigeminal ganglion, then into the brainstem and upward to the thalamus, hypothalamus, and other brain regions involved in processing pain. Those signals also converge with nerves from the skin around your eyes and the muscles of your scalp, which is why migraines often produce pain behind the eyes, across the forehead, and deep into the temples simultaneously.
As the trigeminal nerve fibers activate, they release powerful signaling molecules. The most important is a peptide called CGRP, the strongest known dilator of blood vessels in the brain. CGRP widens blood vessels, triggers inflammation, and causes nearby immune cells called mast cells to release even more inflammatory chemicals. This creates a self-reinforcing loop: inflammation activates more nerve fibers, which release more CGRP, which worsens inflammation. Blood levels of CGRP are measurably elevated during a migraine attack, confirming its central role.
How Brain Chemistry Sets the Stage
Serotonin, a neurotransmitter most people associate with mood, plays a critical role in migraine. People who get migraines tend to have lower baseline serotonin levels. Since serotonin normally helps constrict blood vessels, low levels leave vessels more vulnerable to dilation triggered by CGRP and nitric oxide, another vasodilator. When serotonin drops further, there’s nothing to counterbalance the dilation, and pain intensifies. This is why the most widely used migraine-stopping medications work by mimicking serotonin at receptors on the trigeminal nerve and cranial blood vessels, bringing CGRP levels back down.
The interplay between these two systems, low serotonin and high CGRP, essentially determines how severe an attack becomes. When serotonin is adequately replenished during an attack, it both lowers CGRP and opposes nitric oxide’s vessel-widening effects, tackling the pain from two directions at once.
Cortical Spreading Depression and Aura
About a quarter of migraine sufferers experience aura: visual disturbances like flashing lights, zigzag lines, or temporary blind spots that precede the headache by 20 to 60 minutes. The biological cause is a phenomenon called cortical spreading depression, a slow-moving wave of intense electrical activity that rolls across the surface of the brain. This wave nearly completely shuts down normal brain cell activity for several minutes as it passes, which produces the visual and sensory symptoms of aura.
Cortical spreading depression also appears to directly activate the trigeminovascular pain system, acting as a bridge between the aura phase and the headache that follows. The wave requires the coordinated opening of calcium channels and specific receptors on brain cells. Once a threshold level of activation is reached, the wave becomes self-sustaining and propagates on its own. Even in migraines without aura, similar subthreshold electrical disturbances may occur without producing noticeable visual symptoms but still contribute to triggering the pain cascade.
Genetics and Inherited Susceptibility
Migraine has a strong genetic component. A large genome-wide study of over 102,000 migraine cases identified 123 locations in the genome associated with migraine risk. Some of these genetic variations are specific to migraine with aura (including variations in the CACNA1A gene, which is also linked to a rare inherited form of severe migraine called familial hemiplegic migraine). Others affect migraine regardless of subtype, including variations near genes involved in temperature sensing and vascular function.
Notably, the identified risk genes include those encoding CGRP itself and the serotonin receptor targeted by newer migraine medications. This means some people are essentially wired at the genetic level to produce more of the pain-amplifying signals or to respond more intensely to triggers that wouldn’t bother someone without these variants. If one or both of your parents get migraines, your own susceptibility is significantly higher.
Hormonal Triggers
Roughly 60% of women with migraines notice a clear link to their menstrual cycle, and the explanation lies in estrogen. The estrogen withdrawal hypothesis, first proposed decades ago and now well-supported, holds that the sharp drop in estrogen levels in the days just before menstruation triggers migraine attacks. It’s not low estrogen itself that’s the problem but the rate of decline. Stable low estrogen (as in menopause, after the transition period) or stable high estrogen (as in mid-pregnancy) are generally not migraine triggers.
This hormonal sensitivity explains several patterns women commonly notice: migraines improving during the second and third trimesters of pregnancy when estrogen is consistently high, worsening during perimenopause when estrogen fluctuates unpredictably, and attacks clustering around the first day or two of their period when estrogen reaches its lowest point.
Environmental and Dietary Triggers
Weather changes are one of the most commonly reported migraine triggers, and the data supports this. A study tracking atmospheric pressure and migraine onset found that attacks were most frequently triggered when barometric pressure dropped 6 to 10 points below standard atmospheric pressure (roughly the drop associated with an approaching storm system). About one in four susceptible patients developed a migraine when pressure fell into this range.
Dietary triggers vary from person to person, but tyramine, found in aged cheeses, cured meats, and fermented foods, is among the most studied. Tyramine appears to trigger migraines not through a direct mechanism but by stimulating the adrenergic (adrenaline-related) system. In clinical testing, the likelihood of a migraine correlated directly with the amount of tyramine exposure. Other commonly reported food triggers include alcohol (especially red wine), foods containing nitrates, chocolate, and caffeine withdrawal. The key word is “commonly reported,” because individual sensitivity varies enormously. A food diary tracking your intake and migraine timing over several weeks is the most reliable way to identify your personal triggers.
What Makes Migraines Become Chronic
Each year, roughly 2.5 to 3% of people with episodic migraine (fewer than 15 headache days per month) progress to chronic migraine (15 or more days per month). That number sounds small, but over years the cumulative risk is substantial. The strongest predictor is how frequently you’re already getting migraines. Having 10 or more headache days per month makes you nearly six times more likely to transition to chronic migraine compared to someone with fewer headache days.
Having five or more headache days per month triples the risk. Depression is another significant predictor, raising the likelihood by about 58%. Medication overuse, particularly taking acute pain relief on more than 10 to 15 days per month, carries the highest individual risk ratio of any factor studied, nearly nine times the baseline risk. On the protective side, higher household income (likely a proxy for better access to preventive care and lower overall stress burden) was associated with reduced risk of progression.
These findings highlight why treating migraines early and consistently matters. Letting attacks go unmanaged or relying too heavily on acute medications can, paradoxically, make the condition worse over time. Preventive treatment becomes increasingly important as attack frequency climbs above four or five per month.
How Severe Migraine Is Defined Clinically
The International Headache Society defines migraine as at least five attacks lasting between 4 and 72 hours (untreated), with specific pain characteristics: typically one-sided, pulsating, moderate to severe in intensity, and worsened by routine physical activity like walking or climbing stairs. Nausea, vomiting, or sensitivity to light and sound must also be present. In children and adolescents, attacks can be shorter, lasting as little as two hours, and the pain is more often felt on both sides of the head.
Severity within this framework exists on a spectrum. What pushes a migraine from moderate to severe is often the combination of intense pain with debilitating associated symptoms: vomiting that prevents keeping medication down, extreme light sensitivity that forces you into a dark room, or pain that makes any movement unbearable. The biological mechanisms are the same, but the degree of trigeminovascular activation and the individual’s genetic and hormonal vulnerability determine where on that spectrum any given attack falls.